# EDGAR Filing Document

**Accession Number:** 0001798749
**File Stem:** 0001193125-26-187069
**Filing Date:** 2026-4
**Character Count:** 5307
**Document Hash:** 615d22ebdf57e0f7dea86c85242d6cdb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-187069.hdr.sgml**: 20260428

**ACCESSION NUMBER**: 0001193125-26-187069

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260428

**DATE AS OF CHANGE**: 20260428

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Jade Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001798749
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 831377888
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40544
- **FILM NUMBER:** 26907937

**BUSINESS ADDRESS:**
- **STREET 1:** 221 CRESCENT ST.
- **STREET 2:** BUILDING 23, SUITE 105
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453
- **BUSINESS PHONE:** (781) 312-3013

**MAIL ADDRESS:**
- **STREET 1:** 221 CRESCENT ST.
- **STREET 2:** BUILDING 23, SUITE 105
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aerovate Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20200103

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

**SCHEDULE 14A** 

**SCHEDULE 14A INFORMATION** 

**PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE** 

**SECURITIES EXCHANGE ACT OF 1934** 

**(Amendment No.)** 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))** 

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material under §240.14a-12

**Jade Biosciences, Inc.** 

**(Name of Registrant as Specified in Its Charter)** 

**(Name of Person(s) Filing Proxy Statement, if other Than the Registrant)** 

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required

☐ Fee paid previously with preliminary materials

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

------

![LOGO](g116556snap22.jpg)

Your vote <br>matters! <br>Jade Biosciences, Inc. <br>Annual Meeting of Stockholders <br>Tuesday, June 9, 2026 9:00 AM, Pacific Time <br>Annual Meeting to be held live via the Internet - please visit www.proxydocs.com/JBIO for more <br>details. <br>You must register to attend the meeting online and/or participate at <br>www.proxydocs.com/JBIO <br>For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/JBIO <br>To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. <br>This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. <br>Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. <br>If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 29, 2026. <br>Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K <br>Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 9, 2026 for Stockholders of Record as of April 17, 2026 <br>To order paper materials, use one of the following methods. <br>Internet: <br>www.investorelections.com/JBIO <br>Call: <br>1-866-648-8133<br>Email: <br>paper@investorelections.com <br>\* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. <br>Have the 12 digit control number located in the box above available when you access the website and follow the instructions. <br>SEE REVERSE FOR FULL AGENDA <br>Copyright© 2026 BetaNXT, Inc. or its affiliates. All Rights Reserved

------

![LOGO](g116556snap23.jpg)

Jade Biosciences, Inc. Annual Meeting of Stockholders <br>THE BOARD OF DIRECTORS RECOMMENDS A VOTE: <br>FOR EACH OF THE NOMINEES IN PROPOSAL 1 AND <br>FOR PROPOSALS 2 AND 3 <br>PROPOSAL <br>1. To elect two Class II Directors to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified; <br>1.1 Christopher Cain, Ph.D. <br>1.2 Tom Frohlich <br>2. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; <br>3. To approve an amendment to our Articles of Incorporation to waive jury trials in certain circumstances; and <br>4. To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment thereof.